Clinical Trials Browser

Lymphoma, Extranodal NK-T-Cell × tislelizumab × 1 year × Clear all

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell